

## References

### Hawthorn

- 6250**  
Bourin M, Bougerol T, Guitton B, Broutin E. A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: controlled study vs placebo. *Fundam Clin Pharmacol* 1997;11:127-32. [View abstract.](#)
- 7726**  
Hertog MG, Feskens EJ, Hollman PC, et al. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. *Lancet* 1993;342:1007-1011. [View abstract.](#)
- 8279**  
Schmidt U, Kuhn U, Ploch M, Hubner WD. Efficacy of the Hawthorne (Crataegus) Preparation LI 132 in 78 patients with chronic congestive heart failure defined as NYHA functional class II. *Phytomedicine* 1994;1:17-24. [View abstract.](#)
- 8280**  
Zapfe jun G. Clinical efficacy of crataegus extract WS 1442 in congestive heart failure NYHA class II. *Phytomedicine* 2001;8:262-6. [View abstract.](#)
- 8281**  
Tauchert M. Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. *Am Heart J* 2002;143:910-5. [View abstract.](#)
- 10144**  
Pittler MH, Schmidt K, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. *Am J Med* 2003;114:665-74.. [View abstract.](#)
- 11449**  
Degenring FH, Suter A, Weber M, Saller R. A randomised double blind placebo controlled clinical trial of a standardised extract of fresh Crataegus berries (Crataegisan) in the treatment of patients with congestive heart failure NYHA II. *Phytomedicine* 2003;10:363-9. [View abstract.](#)
- 11450**  
Schwinger RH, Pietsch M, Frank K, Brixius K. Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. *J Cardiovasc Pharmacol* 2000;35:700-7. [View abstract.](#)
- 11451**  
Jouad H, Lemhadri A, Maghrani M, et al. Hawthorn evokes a potent anti-hyperglycemic capacity in streptozotocin-induced diabetic rats. *Journal of Herbal Pharmacotherapy* 2003;3:19-29.
- 12583**  
Hanus M, Lafon J, Mathieu M. Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders. *Curr Med Res Opin* 2004;20:63-71. [View abstract.](#)
- 12595**  
Chang Q, Zuo Z, Harrison F, Chow MS. Hawthorn. *J Clin Pharmacol* 2002;42:605-12. [View abstract.](#)
- 16824**  
Zick SM, Gillespie B, Aaronson KD. The effect of Crataegus oxyacantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. *Eur J Heart Fail* 2008;10:587-93. [View abstract.](#)
- 17203**  
Holubarsch CJ, Colucci WS, Meinertz T, et al. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. *Eur J Heart Fail* 2008;10:1255-63. [View abstract.](#)
- 18222**  
Zand J, Lanza F, Garg HK, Bryan NS. All-natural nitrite and nitrate containing dietary supplement promotes nitric oxide production and reduces triglycerides in humans. *Nutr Res* 2011;31(4):262-9. [View abstract.](#)
- 19201**

- Von Eiff M, Brunner H, Haegeli A, et al. Hawthorn / passion flower extract and improvement in physical exercise capacity of patients with dyspnoea Class II of the NYHA functional classifications. *Acta Therapeutica* 1994;20:47-66. **19221**
- Pittler MH, Guo R, and Ernst E. Hawthorn extract for treating chronic heart failure. *Cochrane.Database.Syst Rev* 2008:CD005312. [View abstract](#). **19222**
- Zick SM, Vautaw BM, Gillespie B, Aaronson KD. Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial. *Eur J Heart Fail.* 2009;11:990-99. [View abstract](#). **19223**
- Forster A, Forster K, Buhring M, et al. Crataegus bei massig reduzierter linksventrikularer Auswurfraction. Ergospirometrische Verlaufsuntersuchung bei 72 Patienten in doppel-blindem Vergleich mit Plazebo. [Crataegus for moderately reduced left ventricular ejection fraction. Ergospirometric monitoring study with 72 patients in a double-blind comparison with placebo]. *Munch Med Wschr* 1994;136:s21-s26. **19225**
- Iwamoto M, Sato T, Ishizaki T. [The clinical effect of Crataegus in heart disease of ischemic or hypertensive origin. A multicenter double-blind study]. *Planta Med* 1981;42:1-16. [View abstract](#). **19226**
- Von Holubarsch, CJ, Niestroj M, Wassmer A, et al. [Hawthorn extract WS 1442 in the treatment of patients with heart failure and LVEF of 25%-35%]. *MMW.Fortschr.Med* 7-1-2010;152:56-61. [View abstract](#). **19227**
- Weikl A, Assmus KD, Neukum-Schmidt A, et al. [Crataegus Special Extract WS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II)]. *Fortschr Med* 1996;114:291-6. [View abstract](#). **19228**
- Leuchtgens H. [Crataegus Special Extract WS 1442 in NYHA II heart failure. A placebo controlled randomized double-blind study]. *Fortschr Med* 1993;111:352-4. [View abstract](#). **19230**
- Tauchert M, Ploch M, and Hubner WD. Effectiveness of hawthorn extract LI 132 compared with the ACE inhibitor Captopril: Multicenter double-blind study with 132 NYHA Stage II. *Munch Med Wochenschr* 1994;136:S27-S33. **19240**
- Werner NS, Duschek S, and Schandry R. D-camphor-crataegus berry extract combination increases blood pressure and cognitive functioning in the elderly - a randomized, placebo controlled double blind study. *Phytomedicine.* 2009;16:1077-82. [View abstract](#). **19241**
- Dalli E, Colomer E, Tormos MC, et al. Crataegus laevigata decreases neutrophil elastase and has hypolipidemic effect: a randomized, double-blind, placebo-controlled trial. *Phytomedicine.* 6-15-2011;18:769-75. [View abstract](#). **19242**
- Weng WL, Zhang WQ, Liu FZ, and et al. Therapeutic effect of Crataegus pinnatifida on 46 cases of angina pectoris--a double blind study. *J Tradit Chin Med* 1984;4:293-94. [View abstract](#). **19243**
- Maek-a-nantawat W, Phonrat B, Dhitavat J, et al. Safety and efficacy of CKBM-A01, a Chinese herbal medicine, among asymptomatic HIV patients. *Southeast Asian J Trop.Med Public Health* 2009;40:494-501. [View abstract](#). **19244**
- Asher GN, Viera AJ, Weaver MA, et al. Effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: a randomized, controlled cross-over trial. *BMC.Complement Altern.Med* 2012;12:26. [View abstract](#). **19245**
- Walker AF, Marakis G, Simpson E, et al. Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trial. *Br J Gen.Pract* 2006;56:437-43. [View abstract](#). **19246**

- Shi KQ, Fan YC, Liu WY, et al. Traditional Chinese medicines benefit to nonalcoholic fatty liver disease: a systematic review and meta-analysis. *Mol.Biol Rep.* 2012;39:9715-22. [View abstract.](#)  
**19247**
- Daniele C, Mazzanti G, Pittler MH, et al. Adverse-event profile of *Crataegus* spp.: a systematic review. *Drug Saf* 2006;29:523-35. [View abstract.](#)  
**19249**
- Tankanow R, Tamer HR, Streetman DS, et al. Interaction study between digoxin and a preparation of hawthorn (*Crataegus oxyacantha*). *J.Clin.Pharmacol.* 2003;43:637-42. [View abstract.](#)  
**39567**
- Schmidt, U., Albrecht, M., and Schmidt, S. [Effects of an herbal crataegus-camphor combination on the symptoms of cardiovascular diseases]. *Arzneimittelforschung* 2000;50(7):613-619. [View abstract.](#)  
**39581**
- Belz, G. G., Butzer, R., Gaus, W., and Loew, D. Camphor-Crataegus berry extract combination dose-dependently reduces tilt induced fall in blood pressure in orthostatic hypotension. *Phytomedicine.* 2002;9(7):581-588. [View abstract.](#)  
**39588**
- Belz, G. G. and Loew, D. Dose-response related efficacy in orthostatic hypotension of a fixed combination of D-camphor and an extract from fresh crataegus berries and the contribution of the single components. *Phytomedicine.* 2003;10 Suppl 4:61-67. [View abstract.](#)  
**42200**
- Hertog MG, Kromhout D, Aravanis C, and et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. *Arch Intern Med* 2-27-1995;155(4):381-386. [View abstract.](#)  
**43966**
- Islam, J., Uretsky, B. F., and Sierpina, V. S. Heart failure improvement with CoQ10, Hawthorn, and magnesium in a patient scheduled for cardiac resynchronization-defibrillator therapy: a case study. *Explore.(NY)* 2006;2(4):339-341. [View abstract.](#)  
**50717**
- Ling, S., Nheu, L., Dai, A., Guo, Z., and Komesaroff, P. Effects of four medicinal herbs on human vascular endothelial cells in culture. *Int J Cardiol.* 8-29-2008;128(3):350-358. [View abstract.](#)  
**54638**
- Al Makdessi S, Sweidan H, DietzK, and et al. Protective effect of *Crataegus oxyacantha* against reperfusion arrhythmias after global no-flow ischemia in the rat heart. *Basic Res Cardiol* 1999;94(2):71-77. [View abstract.](#)  
**54639**
- Muller, A., Linke, W., and Klaus, W. *Crataegus* extract blocks potassium currents in guinea pig ventricular cardiac myocytes. *Planta Med* 1999;65(4):335-339. [View abstract.](#)  
**54640**
- Tauchert, M., Gildor, A., and Lipinski, J. [High-dose *Crataegus* extract WS 1442 in the treatment of NYHA stage II heart failure]. *Herz* 1999;24(6):465-474. [View abstract.](#)  
**54641**
- Min, B. S., Kim, Y. H., Lee, S. M., Jung, H. J., Lee, J. S., Na, M. K., Lee, C. O., Lee, J. P., and Bae, K. Cytotoxic triterpenes from *Crataegus pinnatifida*. *Arch Pharm Res* 2000;23(2):155-158. [View abstract.](#)  
**54642**
- Holubarsch, C. J., Colucci, W. S., Meinertz, T., Gaus, W., and Tendera, M. Survival and prognosis: investigation of *Crataegus* extract WS 1442 in congestive heart failure (SPICE)--rationale, study design and study protocol. *Eur J Heart Fail.* 2000;2(4):431-437. [View abstract.](#)  
**54643**
- Rothfuss, M. A., Pascht, U., and Kissling, G. Effect of long-term application of *Crataegus oxyacantha* on ischemia and reperfusion induced arrhythmias in rats. *Arzneimittelforschung* 2001;51(1):24-28. [View abstract.](#)  
**54644**
- Zhang, Z., Chang, Q., Zhu, M., Huang, Y., Ho, W. K., and Chen, Z. Characterization of antioxidants present in hawthorn fruits. *J Nutr Biochem* 2001;12(3):144-152. [View abstract.](#)

- 54645**
- Schroder, D., Weiser, M., and Klein, P. Efficacy of a homeopathic *Crataegus* preparation compared with usual therapy for mild (NYHA II) cardiac insufficiency: results of an observational cohort study. *Eur.J.Heart Fail.* 2003;5(3):319-326. [View abstract.](#)
- 54646**
- Rehcinski, T. and Kurpesa, M. [Oligomeric procyanidins from hawthorn extract as supplementary therapy in patients with left ventricle systolic dysfunction]. *Przegl.Lek.* 2005;62(4):243-244. [View abstract.](#)
- 54647**
- Zick, S. M., Blume, A., and Aaronson, K. D. The prevalence and pattern of complementary and alternative supplement use in individuals with chronic heart failure. *J Card Fail.* 2005;11(8):586-589. [View abstract.](#)
- 54648**
- Fan, C., Yan, J., Qian, Y., Wo, X., and Gao, L. Regulation of lipoprotein lipase expression by effect of hawthorn flavonoids on peroxisome proliferator response element pathway. *J Pharmacol Sci* 2006;100(1):51-58. [View abstract.](#)
- 54649**
- Koller, M., Lorenz, W., Aubke, W., Jensen, A., Gerlach, F. M., Kuhl, J., Pfeil, T., Regitz-Zagrosek, V., Rusche, H., and Rychlik, R. [*Crataegus* special extract WS 1442 in the treatment of early stages of CHD-associated heart failure]. *MMW Fortschr Med* 2-9-2006;148(6):42. [View abstract.](#)
- 54650**
- Hu, L. and Xiong, C. L. [The influence of medicated serum with root of *Crataegus cuneata* on human sperm motility parameters in vitro]. *Zhongguo Zhong.Yao Za Zhi.* 2006;31(4):333-335. [View abstract.](#)
- 54651**
- Zuo, Z., Zhang, L., Zhou, L., Chang, Q., and Chow, M. Intestinal absorption of hawthorn flavonoids--in vitro, in situ and in vivo correlations. *Life Sci* 11-25-2006;79(26):2455-2462. [View abstract.](#)
- 54652**
- Hosseinimehr, S. J., Mahmoudzadeh, A., Azadbakht, M., and Akhlaghpour, S. Radioprotective effects of Hawthorn against genotoxicity induced by gamma irradiation in human blood lymphocytes. *Radiat.Environ.Biophys.* 2009;48(1):95-98. [View abstract.](#)
- 54653**
- Furey, A. and Tassell, M. Towards a systematic scientific approach in the assessment of efficacy of an herbal preparation: Hawthorn (*Crataegus* spp.). *Eur J Heart Fail.* 2008;10(12):1153-1157. [View abstract.](#)
- 54654**
- Horoz, M., Gok, E., Genctoy, G., Ozcan, T., Olmaz, R., Akca, M., Kiykim, A., and Gurses, I. *Crataegus orientalis* associated multiorgan hypersensitivity reaction and acute renal failure. *Intern.Med* 2008;47(23):2039-2042. [View abstract.](#)
- 54655**
- Gorret, J., Chevalier, J., Gaschet, A., Fraisse, B., Violas, P., Chapuis, M., and Jolivet-Gougeon, A. Childhood delayed septic arthritis of the knee caused by *Serratia fonticola*. *Knee.* 2009;16(6):512-514. [View abstract.](#)
- 54656**
- Baklykova, O. B., Sizova, ZhM, and Shikh, E. V. [Possible use of standardized *Crataegus sanguinea* extract in correction of cardiac rhythm impairment in patients with chronic heart failure]. *Antibiot.Khimioter.* 2009;54(1-2):47-52. [View abstract.](#)
- 54657**
- Raudonis, R., Jakstas, V., Burdulis, D., Benetis, R., and Janulis, V. Investigation of contribution of individual constituents to antioxidant activity in herbal drugs using postcolumn HPLC method. *Medicina (Kaunas.)* 2009;45(5):382-394. [View abstract.](#)
- 54658**
- Harris, E. J. Retained Hawthorn fragment in a child's foot complicated by infection: diagnosis and excision aided by localization with ultrasound. *J Foot Ankle Surg.* 2010;49(2):161-165. [View abstract.](#)
- 54659**

- Moon, H. I., Kim, T. I., Cho, H. S., and Kim, E. K. Identification of potential and selective collagenase, gelatinase inhibitors from *Crataegus pinnatifida*. *Bioorg.Med Chem Lett.* 2010;20(3):991-993. [View abstract.](#) **54660**
- Mahmood, Z. A., Sualeh, M., Mahmood, S. B., and Karim, M. A. Herbal treatment for cardiovascular disease the evidence based therapy. *Pak J Pharm Sci* 2010;23(1):119-124. [View abstract.](#) **54661**
- Crataegus oxyacantha* (Hawthorn). Monograph. *Altern.Med Rev.* 2010;15(2):164-167. [View abstract.](#) **54662**
- Rasmussen, P. Hawthorn--*Crataegus monogyna* (common hawthorn) or *Crataegus laevigata* (midland hawthorn; *Crataegus oxyacantha*); also known as haw, thornapple, maythorn, whitethorn. *J Prim.Health Care* 2011;3(1):63-64. [View abstract.](#) **54663**
- Francis, M. J., Doherty, R. R., Patel, M., Hamblin, J. F., Ojaimi, S., and Korman, T. M. *Curtobacterium flaccumfaciens* septic arthritis following puncture with a Coxspur Hawthorn thorn. *J Clin Microbiol.* 2011;49(7):2759-2760. [View abstract.](#) **54664**
- Dalli, E., Valles, J., Cosin-Sales, J., Santos, M. T., Moscardo, A., Milara, J., and Sotillo, J. F. Effects of hawthorn (*Crataegus laevigata*) on platelet aggregation in healthy volunteers. *Thromb.Res* 2011;128(4):398-400. [View abstract.](#) **54665**
- Zumdick, S., Deters, A., and Hensel, A. In vitro intestinal transport of oligomeric procyanidins (DP 2 to 4) across monolayers of Caco-2 cells. *Fitoterapia* 2012;83(7):1210-1217. [View abstract.](#) **54666**
- O'Conolly M, Jansen W, Bernhoft G, and et al. [Treatment of decreasing cardiac performance. Therapy using standardized crataegus extract in advanced age]. *Fortschr Med* 11-13-1986;104(42):805-808. [View abstract.](#) **54667**
- Mavers WH and Hensel H. [Changes in local myocardial blood circulation following oral administration of a *Crataegus* extract in non-narcotized dogs]. *Arzneimittelforschung* 1974;24(5):783-785. [View abstract.](#) **54668**
- Beier A, Konigstein RP, and Samec V. [Clinical experiences with a crataegus pentaerythryl-tetranitrate combination drug in heart diseases due to coronary sclerosis in old age]. *Wien Med Wochenschr* 6-15-1974;124(24):378-381. [View abstract.](#) **54669**
- Roddewig C and Hensel H. [Reaction of local myocardial blood flow in non-anesthetized dogs and anesthetized cats to the oral and parenteral administration of a *Crataegus* fraction (oligomere procyanidines)]. *Arzneimittelforschung* 1977;27(7):1407-1410. [View abstract.](#) **54670**
- Rogov VD. [Toxiderma due to the fruits of the hawthorn]. *Vestn Dermatol Venerol* 1984;7(7):46-47. [View abstract.](#) **54671**
- Ammon HP and Handel M. [*Crataegus*, toxicology and pharmacology, Part I: Toxicity (author's transl)]. *Planta Med* 1981;43(2):105-120. [View abstract.](#) **54672**
- Ammon HP and Handel M. [*Crataegus*, toxicology and pharmacology. Part II: Pharmacodynamics (author's transl)]. *Planta Med* 1981;43(3):209-239. [View abstract.](#) **54673**
- Ammon HP and Handel M. [*Crataegus*, toxicology and pharmacology. Part III: Pharmacodynamics and pharmacokinetics] (author's transl)]. *Planta Med* 1981;43(4):313-322. [View abstract.](#) **54674**
- Schussler M, Holzl J, and Fricke U. Myocardial effects of flavonoids from *Crataegus* species. *Arzneimittelforschung* 1995;45(8):842-845. [View abstract.](#)

- 54675**
- Vibes, J., Lasserre, B., Gleye, J., and Declume, C. Inhibition of thromboxane A2 biosynthesis in vitro by the main components of Crataegus oxyacantha (Hawthorn) flower heads. Prostaglandins Leukot Essent Fatty Acids 1994;50(4):173-175. [View abstract.](#)
- 54676**
- Nasa Y, Hashizume H, Hoque AN, and et al. Protective effect of crataegus extract on the cardiac mechanical dysfunction in isolated perfused working rat heart. Arzneimittelforschung 1993;43(9):945-949. [View abstract.](#)
- 54677**
- Joseph G, Zhao Y, and Klaus W. [Pharmacologic action profile of crataegus extract in comparison to epinephrine, amrinone, milrinone and digoxin in the isolated perfused guinea pig heart]. Arzneimittelforschung 1995;45(12):1261-1265. [View abstract.](#)
- 54678**
- Weihmayr T and Ernst E. [Therapeutic effectiveness of Crataegus]. Fortschr Med 1-20-1996;114(1-2):27-29. [View abstract.](#)
- 54679**
- Rajendran S, Deepalakshmi PD, Parasakthy K, and et al. Effect of tincture of Crataegus on the LDL-receptor activity of hepatic plasma membrane of rats fed an atherogenic diet. Atherosclerosis 1996;123(1-2):235-241. [View abstract.](#)
- 54680**
- Al Makdessi S, Sweidan H, Mullner S, and et al. Myocardial protection by pretreatment with Crataegus oxyacantha: an assessment by means of the release of lactate dehydrogenase by the ischemic and reperfused Langendorff heart. Arzneimittelforschung 1996;46(1):25-27. [View abstract.](#)
- 54681**
- Rakotoarison DA, Gressier B, Trotin F, and et al. Antioxidant activities of polyphenolic extracts from flowers, in vitro callus and cell suspension cultures of Crataegus monogyna. Pharmazie 1997;52(1):60-64. [View abstract.](#)
- 54682**
- Chatterjee SS, Koch E, Jaggy H, and et al. [In vitro and in vivo studies on the cardioprotective action of oligomeric procyanidins in a Crataegus extract of leaves and blooms]. Arzneimittelforschung 1997;79:821-825. [View abstract.](#)
- 54683**
- Schmidt U, Kuhn U, Ploch M, and et al. Efficacy of the hawthorn extract LI 132 (600mg/d) during eight weeks' treatment. Placebo-controlled double-blind trial with 78 NYHA stage II heart failure patients. Munch Med Wochenschr 1994;136(suppl 1):s13-s19.
- 54684**
- Ventura P, Girola M, and Lattuada V. [Clinical evaluation and tolerability of a drug with garlic and hawthorn]. Acta Toxicol Ther 1990;11(4):365-372.
- 54685**
- Hanack T and Bruckel MH. [The treatment of mild stable forms of angina pectoris using Crategutt novo]. Therapiewoche 1983;33:4331-4333.
- 54686**
- O'Conolly M, Bernhoft G, and Bartsch G. [Treatment of stenocardia (Angina pectoris) pain in advanced age patients with multi-morbidity]. Therapiewoche 1987;37:3587-3600.
- 54687**
- Bodigheimer K and Chase D. [Effectiveness of hawthorn extract at a dosage of 3x100mg per day]. Munch Med Wschr 1994;136 Suppl 1:s7-s11.
- 54688**
- Forster A, Forster K, Buhring M, and et al. Crataegus bei massig reduzierter linksventrikularer Auswurffraktion. Ergospirometrische Verlaufsuntersuchung bei 72 Patienten in doppel-blindem Vergleich mit Plazebo. [Crataegus for moderately reduced left ventricular ejection fraction. Ergospirometric monitoring study with 72 patients in a double-blind comparison with placebo]. Munch Med Wschr 1994;136(suppl 1):s21-s26.
- 54689**

Schmidt U, Kuhn U, Ploch M, and et al. Efficacy of hawthorn (crataegus) preparation LI 132 in 78 patients with chronic congestive heart failure defined as NYHA functional class II. *Phytomedicine* 1994;1:17-24.

**54690**

Tauchert M, Ploch M, and Hubner WD. Effectiveness of hawthorn extract LI 132 compared with the ACE inhibitor Captopril: Multicenter double-blind study with 132 NYHA Stage II. *Munch Med Wochenschr* 1994;136(suppl. 1):S27-S33.

**54691**

Schlegelmilch R and Heywood R. Toxicity of Crataegus (hawthorn) extract (WS 1442). *J Am Coll Toxicol* 1994;13(2):103-111.

**54692**

Loew D, Albrecht M, and Podzuweit H. Efficacy and tolerability of a Hawthorn preparation in patients with heart failure Stage I and II according to NYHA - a surveillance study. *Phytomedicine* 1996;3(Suppl 1):92.

**54693**

Von Eiff M, Brunner H, Haegeli A, and et al. Hawthorn/passion flower extract and improvement in physical exercise capacity of patients with dyspnoea class II of the NYHA functional classification. *Acta Therapeutica* 1994;20:47-66.

**54694**

Petkov V. Plants with hypotensive, antiatheromatous and coronarodilatating action. *Am J Chinese Med* 1979;7(3):197-236.

**54695**

Saenz MT, Ahumada MC, and Garcia MD. Extracts from *Viscum* and *Crataegus* are cytotoxic against larynx cancer cells. *Z Naturforsch* 1997;52c:42-44.

**54698**

Brixius K, Frank K, Muench G, and et al. WG 1442 (*Crataegus* spezialextrakt) works at the insufficient human myocardium contractile force-increasing. *Verhandlungen der deutschen Gesellschaft fur Herz und Kreislaufforschung* 1998;30:28-33.

**54699**

Bahorun T, Gressier B, Troitin F, and et al. Oxygen species scavenging activity of phenolic extracts from hawthorn fresh plant organs and pharmaceutical preparations. *Arzneim-Forsch* 1996;46(2):1086-1089.

**54700**

Weikl A and Noh HS. The influence of *Crataegus* on global cardiac insufficiency. *Herz Gefabe* 1993;11:516-524.

**54701**

Liu, P., Konstam, M. A., and Force, T. Highlights of the 2004 scientific sessions of the Heart Failure Society of America, Toronto, Canada, September 12 to 15, 2004. *Journal of the American College of Cardiology* 2005;45(617):625.

**54702**

Eichstadt, H., Stork, T., Mockel, M., and et al. Effectiveness of and tolerance to *Crataegus* extract WS 1442 in patients with heart insufficiency and reduced left ventricular function. *Perfusion* 2001;14:212-217.

**54703**

Alexander, H. A. Clinical effectiveness of *Crataegus* extract LI132 for treating heart insufficiency stage 2 New York: A randomized placebo-controlled double-blind study with n=73 patients. Dissertation (Dr. med). 1995;

**91504**

Erfurt L, Schandry R, Rubenbauer S, Braun U. The effects of repeated administration of camphor-crataegus berry extract combination on blood pressure and on attentional performance- a randomized, placebo-controlled, double-blind study. *Phytomedicine*. 2014;21(11):1349-55.